BUY Conviction3/5 Analysis quality70/100 Price target26 now
The YouTuber highlights CollPlant Biotechnologies for its work in tissue regeneration and organ manufacturing, including soft tissue fillers and 3D bioprinting. The company has a significant collaboration agreement with AbbVie, providing substantial funding, and maintains a strong cash position with minimal debt. While sales growth can be volatile due to milestone payments, the long-term three-year annualized growth is impressive at 136%. Analysts have an average target of $26, though based on a limited number of analysts.
“CollPlant is one I'm personally rooting for making us old-timers young again by developing technologies for tissue regeneration and organ manufacturing.”